Multiplex Bulk and Single Cell Cytokine Profiling Director: Leiqing Zhang, MD, MSc

Overview

Multiplex cytokine profiling from laboratory or patient blood samples has been popular among cancer center investigators over the last 3 years. A custom-made panel of over 60 cytokines, chemokines, and growth factors supported multiple publications. In 2021, we set up single cell cytokine profiling for the first time in Rhode Island. Polyfunctionality strength index and t-SNE plots are

Key Services

provided.

- Multiplex bulk protein panels detect targets from human, mouse, primate, porcine, rat, and other species
- Sample types may include cell culture supernatants, tissue lysates, serum, plasma, saliva urine, and breast milk
- IsoCode Chip detecting 30+ cytokines per cell, measuring the functional phenotype of each immune cell, including innate and adaptive immune

Value Added

- Clinical trial patient's samples (only 25ul of serum or plasma needed);
- The same precious samples could be used by the other purposes


Major Equipment / Technologies

- Luminex[®] 200: the Luminex 200 RUO System is a flow-based bead reader that allows for the multiplexing of up to 100 analyte per sample
- **Isoplexis**: the breakthrough Single-Cell Intracellular Proteome Solution allows users to analyze signaling cascades of many phosphoproteins directly from each single cell


Key Personnel

- Leiging Zhang, Director,
- Email: leiqing_zhang@brown.edu
- Phone: 631 487 6310
- Associate director to be announced

(60-Plex) LXSAHM-60	\$8,02	5				
				Standard		
	Bead	Standard				
Analyte	Region	Cocktail	(pg/mL)		Pla	
Angiopoietin-1	64	ŧ J	94.7 - 230	1:50		
Angiopoietin-2	20	5 D	94.7 - 230			
beta 2-Microglobulin	1	3 K	74.1 - 180	1:4,000	1:4	
C-Reactive Protein/CRP	63	2 B	119 - 2900	0.180556	0.1	
CCL2/JE/MCP-1	2	5 A	30.9 - 750	1:02		
CCL3/MIP-1 alpha	3	5 A	90.5 - 220	1:02		
CCL4/MIP-1 beta	37	7 A	123 - 3000	1:02		
CCL13/MCP-4	3	3 D	4.94 - 120	1:02		
CCL19/MIP-3 beta	43	2 L	10.3 - 250	1:02		
CCL20/MIP-3 alpha	33	3 D	8.23 - 200	1:02		
CCL22/MDC	30	51	53.5 - 130	1:02		
CD27/TNFRSF7	6	7 E	103 - 2500	1:02		
CD40/TNFRSF5	70	5 E	20.6 - 500	1:02		
Chitinase 3-like 1	20) C	412 - 1000	1:02		
Cripto	19) C	45.3 - 110	1:02		
CXCL5/ENA-78	52	2 B	52.3 - 125	1:02		
CXCL11/I-TAC	63	3 B	24.7 - 600	1:02		
CXCL13/BLC/BCA-1	21	3 D	18.5 - 450	1:02		
DcR3/TNFRSF6B	54	ŧ E	453 - 1100	1:02		
DR3/TNFRSF25	7	2 E	510 - 1250	1:02		
Fas/TNFRSF6/CD95	7	B E	144 - 3500	1:02		
Fas Ligand/TNFSF6	35	D	8.23 - 200	1:02		
GDF-15	6	5 C	18.5 - 450	1:02		
GM-CSF	4	5 B	12.3 - 300	1:02		
Granzyme B	57	7 L	19.3 - 470	1:02		
IFN-beta	2	LR	14.1 - 345	1:02		
IFN-gamma	25	A	49.4 - 120	1:02		
IFN-gamma R1/CD119	55	δE	2.88 - 700	1:02		
IL-2	43	3 B	30.9 - 750	1:02		
IL-4	7	5 B	17.3 - 420	1:02		
IL-8/CXCL8	18	3 A	4.12 - 100	1:02		
IL-10	22	2 A	4.12 - 100	1:02		
IL-12 p70	56	5 B	144 - 3500	1:02		
IL-18/IL-1F4	71	3 C	7.12 - 1,73	1:02		
PD-L1/B7-H1	14	ŧ K	4.53 - 110	1:02		
TNF-alpha	12	2 A	8.23 - 200	1:02		
TRAIL R2/TNFRSF10B	44	¥1	20.6 - 500	1:02		
TRAIL R3/TNFRSF10C	74	ŧE	56.8 - 140	1:02		
TRANCE/TNFSF11/RANK L		31	33.7 - 820			
VEGF		LA	8.23 - 200			
CCL5/RANTES		5 A	20.6 - 500			
CXCL10/IP-10/CRG-2		LC	1.65 - 400			



GM-CSF Granzyme B IFN-gamma M-CSF TNF-alpha TRAIL/TNFSF10



human patients with refractory solid tumors of multiple tissue origins enrolled in a Phase 1 clinical trial investigating a novel GSK-3 inhibitor elraglusib (NCT03678883) were analyzed using a Luminex 200 (N = 19).

Example of Scientific Impact



Users Profile



Total samples: 2120

- 1. Aaron Maxwell, MD, Director of Interventional Oncology at The Warren Alpert Medical School of Brown University and Director of the Brown Image-Guided Therapies Research Laboratory, total 328 samples;
- 2. Michelle Dawson, PhD, an Assistant Professor in the Department of Molecular Biology, Cellular Biology and Biochemistry at Brown University, total 82 samples;
- 3. Hongwei Yao, MD, PhD, an Associate Professor (Research) of Molecular Biology, Cell Biology & Biochemistry at Brown University Warren Alpert Medical School, total 82 samples;
- 4. Phyllis A. Dennery, MD, the Sylvia Kay Hassenfeld Chair of Pediatrics at the Warren Alpert School of Medicine of Brown University, total 82 samples;
- 5. Sheldon L. Holder, MD, PhD, a Physician Scientist in the Cancer Center at Brown University, 82 samples;
- 5. Sean Lawler, PhD, Associate Professor of Pathology and Laboratory Medicine, total 82 samples;
- 7. Diane Hoffman-Kim, PhD, an associate Professor of Medical Science and Engineering in the Department of Molecular Pharmacology, Physiology, and Biotechnology and the Center for Biomedical Engineering, total 82 samples;
- 8. Benedito ACarneiro, MD, Associate Professor of Medicine, total 118 samples;
- 9. Andrew Mazar, Actuate Therapeutics, total 1182 samples.

Key Publications

- Yao H, et al. Timing and cell specificity of senescence drives postnatal lung development and injury. Nat Commun. 17;14(1):273. PMID: 36650158
- Huntington KE, et al.Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2.Elife .10:e64958. PMID: 33443016

Future Plans

- Increase user base
- Expand number of consultations provided to researchers and clinicians
- Develop budgetary operations

